Abstract:Since the launch of the first orally available angiotensin II (AngII) type 1 receptor (AT 1 R) blocker (ARB) losartan (Cozaar) in the late 1990s, the class of ARBs (or ‘sartans’, short for Angiotensin-RecepTor-ANtagonistS) quickly expanded to include candesartan, eprosartan, irbesartan, valsartan, telmisartan, and olmesartan. All ARBs have high affinity for the AT 1 receptor, expressed in various tissues, including smooth muscle cells, heart, kidney, and brain. Since activation of AT 1 R, the target of these drugs, leads, among other effects, to vascular smooth muscle cell growth, proliferation and contraction, activation of fibroblasts, cardiac hypertrophy, aldosterone secretion from the adrenal cortex, thirst-fluid intake (hypervolemia), etc., the ARBs are nowadays one of the most useful cardiovascular drug classes used in clinical practice. However, significant differences in their pharmacological and clinical properties exist that may favor use of particular agents over others within the class, and, in fact, two of these drugs, candesartan and valsartan, continuously appear to distinguish themselves from the rest of the ‘pack’ in recent clinical trials. The reason(s) for the potential superiority of these two agents within the ARB class are currently unclear but under intense investigation. The present short review gives an overview of the clinical properties of the ARBs currently approved by the United States Food and Drug Administration, with a particular focus on candesartan and valsartan and the areas where these two drugs seem to have a therapeutic edge. In the second part of our review, we outline recent data from our laboratory (mainly) on the molecular effects of the ARB drugs on aldosterone production and on circulating aldosterone levels, which may underlie (at least in part) the apparent clinical superiority of candesartan (and valsartan) over most other ARBs currently in clinical use.

Research Progress in Pharmacological Mechanisms, Structure-Activity Relationship and Synthesis of Sartans

Small molecule angiotensin converting enzyme inhibitors: A medicinal chemistry perspective

Exploring Hypertension: The Role of AT1 Receptors, Sartans, and Lipid Bilayers

Structural Basis for Ligand Recognition and Functional Selectivity at Angiotensin Receptor.

Progress on the Treatment for Hypertension of Epoxide Hydrolase and Its Mechanisms

Research and Development of the New Drugs Acting on Angiotensin II Receptor

Structural Insights into Angiotensin Receptor Signaling Modulation by Balanced and Biased Agonists.

Design, Synthesis, and Biological Evaluation of 1,2,4-Triazole Bearing 5-Substituted Biphenyl-2-sulfonamide Derivatives As Potential Antihypertensive Candidates

Pharmacological Research Progress of Novel Antihypertensive Drugs

A Patent Review of Aldosterone Synthase Inhibitors (2014-Present)

Chemical Synthesis, Safety and Efficacy of Antihypertensive Candidate Drug 221s (2,9)

Recent developments of synthesis and biological activity of sultone scaffolds in medicinal chemistry

Design, synthesis and biological evaluation of novel fluoro-substituted benzimidazole derivatives with anti-hypertension activities

Design of Novel Thiazole Bearing Pyrazole Derivatives and Their Dual Activities as ACE Inhibitors and Calcium Channel Blockers in Cardiovascular Disease

New flavonoid-based compound synthesis strategy for antihypertensive drug development

Discovery of a new generation of angiotensin receptor blocking drugs: Receptor mechanisms and in silico binding to enzymes relevant to SARS-CoV-2

Summary of Synthesis Methods of Olmesartan Medoxomil and Key Intermediates

Angiotensin Ii Type 1 Receptor Antagonists in Animal Models of Vascular, Cardiac, Metabolic and Renal Disease

The history and mystery of sacubitril/valsartan: From clinical trial to the real world

The new progress in treatment of hypertension

The place of ARBs in heart failure therapy: is aldosterone suppression the key?